Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1982 2
1983 1
1986 2
1987 1
1988 3
1989 2
1990 3
1991 1
1992 1
1993 4
1994 4
1995 1
1997 3
1998 3
1999 6
2000 5
2002 3
2003 7
2004 3
2005 1
2006 5
2007 9
2008 7
2009 9
2010 12
2011 16
2012 10
2013 9
2014 16
2015 10
2016 21
2017 20
2018 22
2019 14
2020 23
2021 28
2022 16
2023 16
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.
[Rehabilitation of hip fractures. Systematic review].
Izaguirre A, Delgado I, Mateo-Troncoso C, Sánchez-Nuncio HR, Sánchez-Márquez W, Luque-Ramos A. Izaguirre A, et al. Among authors: delgado i. Acta Ortop Mex. 2018 Jan-Feb;32(1):28-35. Acta Ortop Mex. 2018. PMID: 30182543 Free article. Spanish.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
Ruiz de Gauna M, Biancaniello F, González-Romero F, Rodrigues PM, Lapitz A, Gómez-Santos B, Olaizola P, Di Matteo S, Aurrekoetxea I, Labiano I, Nieva-Zuluaga A, Benito-Vicente A, Perugorria MJ, Apodaka-Biguri M, Paiva NA, Sáenz de Urturi D, Buqué X, Delgado I, Martín C, Azkargorta M, Elortza F, Calvisi DF, Andersen JB, Alvaro D, Cardinale V, Bujanda L, Banales JM, Aspichueta P. Ruiz de Gauna M, et al. Among authors: delgado i. Hepatology. 2022 Dec;76(6):1617-1633. doi: 10.1002/hep.32344. Epub 2022 Feb 8. Hepatology. 2022. PMID: 35030285 Free PMC article.
International regulatory requirements for skin sensitization testing.
Daniel AB, Strickland J, Allen D, Casati S, Zuang V, Barroso J, Whelan M, Régimbald-Krnel MJ, Kojima H, Nishikawa A, Park HK, Lee JK, Kim TS, Delgado I, Rios L, Yang Y, Wang G, Kleinstreuer N. Daniel AB, et al. Among authors: delgado i. Regul Toxicol Pharmacol. 2018 Jun;95:52-65. doi: 10.1016/j.yrtph.2018.03.003. Epub 2018 Mar 6. Regul Toxicol Pharmacol. 2018. PMID: 29518484 Free PMC article. Review.
Los autores aludidos ofrecieron la siguiente réplica.
Repetto G, Benavides F, Delgado I. Repetto G, et al. Among authors: delgado i. Rev Med Chil. 2016 Apr;144(4):541. doi: 10.4067/S0034-98872016000400022. Rev Med Chil. 2016. PMID: 27401393 Free article. Spanish. No abstract available.
297 results